Jupiter Neurosciences, Inc. (JUNS) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company developing JOTROL, a resveratrol-based therapeutic for neuro-inflammation and rare diseases (e.g., Parkinson's, Friedreich's Ataxia). The company is also transitioning into a dual-segment model, launching the Nugevia brand of premium nutritional supplements. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(2,288,034) | $(591,021) | $(6,069,866) | $(911,998) |
| Operating Expenses | $2,297,053 | $493,547 | $6,099,936 | $1,632,926 |
| Cash and Equivalents | $723,797 | $3,769,510 (Dec 31, 2024) | $723,797 | $253 (Sep 30, 2024) |
| Operating Cash Flow | Not provided for Q3 | Not provided for Q3 | $(3,045,713) | $(215,225) |
| Accumulated Deficit | $(32,091,995) | $(24,494,502) | $(32,091,995) | $(24,494,502) |
| Shares Outstanding | 34,294,546 | 30,126,413 | 34,294,546 | 30,126,413 |
Material Changes vs. Prior Period
- Expense Surge: Operating expenses increased 365% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 274% year-to-date. This was driven by a 789% increase in R&D (due to Asian market development agreements and clinical trial supplies) and a 269% increase in G&A (due to full salary payments, accrued bonuses, and public company compliance costs).
- Interest Expense Reduction: Interest expense dropped 99% in Q3 2025 compared to Q3 2024, as all prior convertible notes were repaid or converted in December 2024.
- Cash Burn: Cash reserves declined from $3.77 million at year-end 2024 to $723,797 at September 30, 2025, reflecting a net cash outflow from operations of $3.05 million for the nine-month period.
- Stock Activity: The company issued shares for warrant exercises and amendments, and corrected an administrative error regarding restricted stock units, reducing the share count from a preliminary June 30 figure.
Outlook, Risks, and Contingencies
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months due to recurring losses, negative cash flows, and reliance on external financing.
- Financing: On October 24, 2025 (subsequent event), the company entered a Standby Equity Purchase Agreement (SEPA) with Yorkville, securing up to $20 million in equity access and receiving an initial $3.72 million pre-paid advance via convertible notes.
- Product Launch: The Nugevia supplement line is expected to launch in Fall 2025. Revenue generation is contingent on successful commercialization.
- Clinical Pipeline: A Phase IIa clinical trial for Parkinson's disease is planned to start in Q4 2025. Success depends on regulatory approvals and clinical efficacy.
- Risks: Key risks include failure to raise capital, inability to commercialize Nugevia, regulatory hurdles for JOTROL, and intense competition in the nutraceutical and pharmaceutical sectors.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $723,797 cash balance against the $3.05 million YTD burn rate and the timing of the Yorkville SEPA funding.
- Accrued Liabilities: Review the $1.85 million in accrued compensation and the conditions for payment (contingent on maintaining $3.5M cash).
- SEPA Terms: Analyze the dilution impact of the Yorkville agreement, including the 19.99% exchange cap and the 8% interest rate on the convertible notes.
- Nugevia Revenue: Monitor Q4 2025 filings for actual revenue recognition from the Nugevia launch, as the company has historically generated zero product revenue.
- Related Party Transactions: Note the repayment of the CEO's related-party loan ($150,782) in October 2025 and ongoing fees to Titan Advisory Services (CFO-owned).